

Supplementary Table 1. Baseline characteristics of patients with stage IV colorectal cancer according to chemotherapy regimen

Variables		5-FU based (n=51)	Oxaliplatin-based (n=52)	<i>p</i> value
Period of surgery	2003-2010	37 (73%)	7 (13%)	<0.0001
	2011-2017	14 (27%)	45 (87%)	
Age, year	Mean ± SD	62.6 ± 10.6	61.3 ± 11.0	0.55
Gender	Male	29 (57%)	30 (58%)	0.93
ECOG PS	0	51 (100%)	50 (96%)	0.10
	1	0 (0%)	2 (4%)	
Hemoglobin, g/dL	Mean ± SD	12.2 ± 1.9	12.0 ± 1.6	0.68
Albumin, g/dL	Mean ± SD	3.8 ± 0.4	3.7 ± 0.5	0.57
CEA	Elevated	38 (75%)	41 (79%)	0.60
CA 19-9	Elevated	20 (39%)	30 (58%)	0.060
Primary site	Right-sided colon	16 (31%)	22 (42%)	0.49
	Left-sided colon	17 (33%)	19 (37%)	
	Rectum	18 (35%)	11 (21%)	
Size of primary cancer, mm	Mean ± SD	54.0 ± 21.9	50.3 ± 19.4	0.36
Obstruction	Yes	24 (46%)	52 (50%)	0.61
Histology	Differentiated ^a	42 (82%)	49 (94%)	0.072
	Others	9 (18%)	3 (6%)	

5-FU, 5-fluorouracil; SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; PS, performance status; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9.

^a differentiated adenocarcinoma.

Supplementary Table 1 (continued). Baseline characteristics of patients with stage IV colorectal cancer according to chemotherapy regimen

Variables		5-FU based	Oxaliplatin-based	<i>p</i> value
		(n=51)	(n=52)	
Depth	-pT3	20 (39%)	19 (37%)	0.78
	pT4	31 (61%)	33 (63%)	
Regional lymph node metastasis	Yes	42 (82%)	44 (85%)	0.76
Lymphatic invasion	Yes	29 (57%)	33 (63%)	0.49
Venous invasion	Yes	44 (86%)	49 (94%)	0.17
<i>KRAS</i> exon 2 status ^b	Wild-type	10 (77%)	16 (46%)	0.10
	Mutant	3 (23%)	19 (54%)	
DNA microsatellite instability ^b	Stable	34 (100%)	45 (100%)	1.00
Number of metastasized Organs	1	45 (96%)	45 (87%)	1.00
	2	6 (4%)	7 (13%)	
Metastasized organs	Liver	37 (73%)	35 (67%)	0.56
	Lung	5 (10%)	3 (6%)	0.49
	Distant lymph nodes	1 (2%)	3 (6%)	0.62
	Peritoneum	14 (27%)	14 (27%)	0.95
	Ovary	0 (0%)	2 (4%)	0.50
	Others	0 (0%)	2 (4%)	0.50
Blood transfusions	Yes	9 (18%)	6 (12%)	0.55
Postoperative complications	Grade 2-	20 (39%)	16 (31%)	0.37

5-FU, 5-fluorouracil.

^b excluding cases that were not evaluated.